Literature DB >> 20815011

Design and synthesis of selective and potent orally active S1P5 agonists.

Henri Mattes1, Kumlesh Kumar Dev, Rochdi Bouhelal, Carmen Barske, Fabrizio Gasparini, Danilo Guerini, Anis Khusro Mir, David Orain, Maribel Osinde, Anne Picard, Celine Dubois, Engin Tasdelen, Samuel Haessig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20815011     DOI： 10.1002/cmdc.201000253

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  5 in total

Review 1.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Authors:  Gregory T Kunkel; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

2.  Novel Potent Selective Orally Active S1P5 Receptor Antagonists.

Authors:  Bin Ma; Kevin M Guckian; Xiao-Gao Liu; Chunhua Yang; Bing Li; Robert Scannevin; Michaël Mingueneau; Annabelle Drouillard; Thierry Walzer
Journal:  ACS Med Chem Lett       Date:  2021-01-15       Impact factor: 4.345

3.  The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.

Authors:  Catherine O'Sullivan; Anna Schubart; Anis K Mir; Kumlesh K Dev
Journal:  J Neuroinflammation       Date:  2016-02-08       Impact factor: 8.322

4.  Fingolimod Rescues Demyelination in a Mouse Model of Krabbe's Disease.

Authors:  Sibylle Béchet; Sinead A O'Sullivan; Justin Yssel; Steven G Fagan; Kumlesh K Dev
Journal:  J Neurosci       Date:  2020-03-03       Impact factor: 6.167

Review 5.  Chemical and genetic tools to explore S1P biology.

Authors:  Stuart M Cahalan
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.